Business Wire

Business Wire is the global leader in news release distribution and regulatory disclosure. Business Wire delivers news and multimedia directly into editorial systems and leading online news platforms and is a trusted source for news organisations, journalists, investment professionals and regulatory authorities.

Results: 6637-6648 of 22715

Valeo Foods Group Recognised for Sustainability Leadership with EcoVadis Platinum Medal

Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage

Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

Lone Star Announces Sale of Xella to Holcim

Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

Business Wire

Valeo Foods Group Recognised for Sustainability Leadership with EcoVadis Platinum Medal

Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage

Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

Lone Star Announces Sale of Xella to Holcim

Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

Kolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure

ProAmpac Acquires International Paper’s Bag Converting Operations

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Qualcomm Announces Quarterly Cash Dividend